세계의 약물 전달 기기 시장 : 투여 경로별, 용도별, 최종사용자별, 지역별 - 시장 규모, 산업 동향, 기회 분석, 예측(2026년-2035년)

The drug delivery devices market has moved beyond a phase of steady growth into a period of rapid expansion, reflecting the increasing complexity and innovation within the healthcare sector. Valued at approximately US$212.6 billion in 2025, the market is projected to nearly double in size, reaching an estimated valuation of US$450.7 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 7.8% over the forecast period from 2026 to 2035, indicating a strong and sustained upward trajectory driven by multiple converging factors.

One of the primary drivers behind this rapid market expansion is the proliferation of biologic therapies, which have become increasingly central to the treatment of a wide range of diseases. The complexity of biologics requires the development of advanced injectable devices capable of delivering these potent medications safely and effectively, often with precise dosing and controlled release mechanisms. In response, manufacturers are innovating new delivery systems that accommodate these sophisticated therapies, fueling demand for specialized drug delivery technologies.

Noteworthy Market Developments

The competitive landscape of the drug delivery devices market is characterized by a dynamic mix of large, diversified healthcare corporations alongside specialized innovators. These players employ a variety of strategies to strengthen their market positions, including mergers and acquisitions (M&A), significant investments in research and development (R&D), and the formation of strategic partnerships. Such activities are driving consolidation within the industry, reshaping the competitive hierarchy, and intensifying the race to capture larger shares of the expanding market.

In December 2025, Phillips Medisize, a Molex company renowned for its expertise in the design, development, engineering, and manufacturing of pharmaceutical drug delivery, in vitro diagnostic, and medtech devices, is set to highlight its inhaled drug delivery device and formulation platforms at the prestigious Drug Delivery to the Lungs conference (DDL 2025). This showcase will demonstrate Phillips Medisize's commitment to innovation and its capacity to advance the capabilities of inhalation therapies, a critical segment within drug delivery technology.

Earlier, in October 2025, a significant partnership was announced between biopharmaceutical giant Incyte, a company valued at $17.8 billion with strong financial health according to InvestingPro analysis, and Enable Injections. The collaboration focuses on leveraging Enable's enFuse On-Body Delivery System to develop and deliver Incyte's investigational therapies.

During the same month, Stevanato Group, a global leader providing drug containment, drug delivery, and diagnostic solutions across the pharmaceutical, biopharmaceutical, and life sciences sectors, announced a substantial expansion of its drug delivery system manufacturing capacity. This move reflects the company's proactive approach to meeting growing market demand and underscores the broader trend of scaling production capabilities to support the evolving needs of the healthcare industry.

Core Growth Drivers

The trajectory of the drug delivery devices market is closely intertwined with the rising prevalence of chronic diseases that necessitate frequent, often lifelong, medication dosing. Chronic conditions such as diabetes and obesity have emerged as the leading consumers of drug delivery devices, alongside cancer, which also requires complex therapeutic regimens. In recent years, treatment protocols for these diseases have evolved significantly, with many patients now shifting toward weekly self-injections. This change has increased the demand for user-friendly, reliable delivery devices that support patient autonomy and adherence to therapy.

Emerging Opportunity Trends

The drug delivery devices market is increasingly shifting toward what is known as "High-Value Solutions," a category of devices characterized by digital connectivity and the ability to manage complex drug formulations. These advanced devices are designed not only to deliver medication but also to provide enhanced functionality such as real-time monitoring, data collection, and integration with digital health platforms. This shift reflects a broader trend toward personalized medicine and connected healthcare, where patients and providers benefit from more precise and interactive treatment options.

Barriers to Optimization

Stringent regulatory requirements represent a major challenge to the growth of the drug delivery devices market. Regulatory agencies like the US Food and Drug Administration (FDA) impose rigorous standards designed to ensure that every product entering the market meets strict criteria for safety, efficacy, and quality. These regulations are essential to protect patient health and maintain trust in medical technologies, but they also create considerable hurdles for manufacturers seeking to introduce innovative devices.

Detailed Market Segmentation

By Route of Administration, Oral administration stands out as the undisputed leader in the drug delivery devices market, largely due to its unparalleled convenience and widespread acceptance among patients and healthcare providers alike. This route of administration offers a non-invasive, easy-to-use method for delivering medications, making it the preferred choice for a broad range of treatments. Its dominance is further reinforced by the vast number of small-molecule drugs, which are particularly well-suited for oral delivery because of their chemical properties and stability.

By Application, Cancer has emerged as the leading application within the drug delivery devices market due to the unique challenges associated with treating malignancies. Effective cancer treatment often requires the precise administration of highly potent and toxic biologic drugs, making accurate dosing and controlled delivery essential to maximize therapeutic outcomes while minimizing harmful side effects. The complexity of oncology therapies, which frequently involve targeted treatments and immunotherapies, has heightened the demand for advanced drug delivery devices capable of managing these sensitive medications with exceptional precision and safety.

By End User, Hospitals represent the largest end-user segment in the drug delivery devices market, primarily because they handle the highest volume of acute care procedures that demand the use of complex infusion systems. These procedures often require precise and reliable delivery of medications, fluids, and other therapies, making advanced drug delivery devices indispensable within hospital settings. The critical nature of hospital care, where timely and accurate drug administration can significantly impact patient outcomes, drives substantial demand for sophisticated delivery tools designed to meet stringent safety and efficacy standards.

Segment Breakdown

By Route of Administration

• Oral
• Ocular
• Inhalation
• Nasal
• Injectable
• Topical
• Others

By Application

• Cardiovascular
• Diabetes
• Cancer
• Infectious Diseases
• Others

By End User

• Hospitals
• Ambulatory Services
• Home Healthcare

By Region

• North America
• The US
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia and New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East and Africa
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

Geography Breakdown

• North America holds a commanding position in the global drug delivery devices market, capturing a dominant market share of approximately 32.72% in 2025. This leadership is deeply rooted in the region's robust and structural growth driven by the rapid commercial expansion of high-value biologics. The increasing adoption of biologic therapies, which are often complex and require specialized delivery mechanisms, has significantly fueled the financial growth of the drug delivery devices sector in North America. This surge in therapeutic consumption underscores the region's pivotal role as a global hub for advanced healthcare solutions.
• Beyond merely consuming these innovative therapies, North America is experiencing a manufacturing renaissance aimed at reshaping its pharmaceutical production landscape. There is a strong strategic push to localize manufacturing capabilities, bringing production closer to the regional market. This shift not only enhances supply chain resilience but also accelerates the delivery of advanced drug delivery devices to patients. By investing in state-of-the-art manufacturing technologies and infrastructure within its borders, North America is reinforcing its dominance in the drug delivery devices market.

Leading Market Participants

• Becton, Dickinson and Company
• 3M
• Antares Pharma
• Bayer AG
• Cipla Inc.
• Enable Injections
• F. Hoffmann-La Roche Ltd
• Gerresheimer AG
• GlaxoSmithKline plc
• Insulet Corporation
• Johnson & Johnson Services, Inc.
• MEDMIX SYSTEMS AG
• Merck & Co., Inc.
• Novartis AG
• Novosanis
• OraSure Technologies, Inc.
• Pfizer Inc.
• Sanofi
• SMC Ltd.
• Sulzer Ltd
• ViVO Smart Medical Devices Ltd.
• West Pharmaceutical Services, Inc.
• Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Drug Delivery Devices Market

Chapter 2. Research Methodology & Research Framework

• 2.1. Research Objective
• 2.2. Product Overview
• 2.3. Market Segmentation
• 2.4. Qualitative Research
  • 2.4.1. Primary & Secondary Sources
• 2.5. Quantitative Research
  • 2.5.1. Primary & Secondary Sources
• 2.6. Breakdown of Primary Research Respondents, By Region
• 2.7. Assumption for Study
• 2.8. Market Size Estimation
• 2.9. Data Triangulation

Chapter 3. Global Drug Delivery Devices Market Overview

• 3.1. Industry Value Chain Analysis
  • 3.1.1. Material Provider
  • 3.1.2. Manufacturer
  • 3.1.3. Distributor
  • 3.1.4. End User
• 3.2. Industry Outlook
• 3.3. PESTLE Analysis
• 3.4. Porter's Five Forces Analysis
  • 3.4.1. Bargaining Power of Suppliers
  • 3.4.2. Bargaining Power of Buyers
  • 3.4.3. Threat of Substitutes
  • 3.4.4. Threat of New Entrants
  • 3.4.5. Degree of Competition
• 3.5. Market Growth and Outlook
  • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.5.2. Price Trend Analysis
• 3.6. Market Attractiveness Analysis
  • 3.6.1. By Segment/Region
  • 3.6.2. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

• 4.1. Market Concentration Rate
• 4.2. Company Market Share Analysis (Value %), 2025
• 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Drug Delivery Devices Market Analysis

• 5.1. Market Dynamics and Trends
  • 5.1.1. Growth Drivers
  • 5.1.2. Restraints
  • 5.1.3. Opportunity
  • 5.1.4. Key Trends
• 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 5.2.1. By Route of Administration
    • 5.2.1.1. Key Insights
      • 5.2.1.1.1. Oral
      • 5.2.1.1.2. Ocular
      • 5.2.1.1.3. Inhalation
      • 5.2.1.1.4. Nasal
      • 5.2.1.1.5. Injectable
      • 5.2.1.1.6. Topical
      • 5.2.1.1.7. Others
  • 5.2.2. By Application
    • 5.2.2.1. Key Insights
      • 5.2.2.1.1. Cardiovascular
      • 5.2.2.1.2. Diabetes
      • 5.2.2.1.3. Cancer
      • 5.2.2.1.4. Infectious Diseases
      • 5.2.2.1.5. Others
  • 5.2.3. By End User
    • 5.2.3.1. Key Insights
      • 5.2.3.1.1. Hospitals
      • 5.2.3.1.2. Ambulatory Services
      • 5.2.3.1.3. Home Healthcare
  • 5.2.4. By Region
    • 5.2.4.1. Key Insights
      • 5.2.4.1.1. North America
        • 5.2.4.1.1.1. The U.S.
        • 5.2.4.1.1.2. Canada
        • 5.2.4.1.1.3. Mexico
      • 5.2.4.1.2. Europe
        • 5.2.4.1.2.1. Western Europe
• 5.2.4.1.2.1.1. The UK
• 5.2.4.1.2.1.2. Germany
• 5.2.4.1.2.1.3. France
• 5.2.4.1.2.1.4. Italy
• 5.2.4.1.2.1.5. Spain
• 5.2.4.1.2.1.6. Rest of Western Europe
  • 5.2.4.1.2.2. Eastern Europe
• 5.2.4.1.2.2.1. Poland
• 5.2.4.1.2.2.2. Russia
• 5.2.4.1.2.2.3. Rest of Eastern Europe
  • 5.2.4.1.3. Asia Pacific
    • 5.2.4.1.3.1. China
    • 5.2.4.1.3.2. India
    • 5.2.4.1.3.3. Japan
    • 5.2.4.1.3.4. South Korea
    • 5.2.4.1.3.5. Australia & New Zealand
    • 5.2.4.1.3.6. ASEAN
    • 5.2.4.1.3.7. Rest of Asia Pacific
  • 5.2.4.1.4. Middle East & Africa
    • 5.2.4.1.4.1. UAE
    • 5.2.4.1.4.2. Saudi Arabia
    • 5.2.4.1.4.3. South Africa
    • 5.2.4.1.4.4. Rest of MEA
  • 5.2.4.1.5. South America
    • 5.2.4.1.5.1. Argentina
    • 5.2.4.1.5.2. Brazil
    • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Drug Delivery Devices Market Analysis

• 6.1. Key Insights
• 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 6.2.1. By Route of Administration
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country

Chapter 7. Europe Drug Delivery Devices Market Analysis

• 7.1. Key Insights
• 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 7.2.1. By Route of Administration
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country

Chapter 8. Asia Pacific Drug Delivery Devices Market Analysis

• 8.1. Key Insights
• 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 8.2.1. By Route of Administration
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country

Chapter 9. Middle East & Africa Drug Delivery Devices Market Analysis

• 9.1. Key Insights
• 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 9.2.1. By Route of Administration
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country

Chapter 10. South America Drug Delivery Devices Market Analysis

• 10.1. Key Insights
• 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 10.2.1. By Route of Administration
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 11.1. Becton, Dickinson and Company
• 11.2. 3M
• 11.3. Antares Pharma
• 11.4. Bayer AG
• 11.5. Cipla Inc.
• 11.6. Enable Injections
• 11.7. F. Hoffmann-La Roche Ltd
• 11.8. Gerresheimer AG
• 11.9. GlaxoSmithKline plc
• 11.10. Insulet Corporation
• 11.11. Johnson & Johnson Services, Inc.
• 11.12. MEDMIX SYSTEMS AG
• 11.13. Merck & Co., Inc.
• 11.14. Novartis AG
• 11.15. Novosanis
• 11.16. OraSure Technologies, Inc.
• 11.17. Pfizer Inc.
• 11.18. Sanofi
• 11.19. SMC Ltd.
• 11.20. Sulzer Ltd
• 11.21. ViVO Smart Medical Devices Ltd.
• 11.22. West Pharmaceutical Services, Inc.
• 11.23. Other Prominent Players

Chapter 12. Annexure

• 12.1. List of Secondary Sources
• 12.2. Key Country Markets- Macro Economic Outlook/Indicators